NCT00269204

Lipid Efficacy/Tolerability Study (0524A-020)

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,620 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of the 3 treatment groups.

Conditions

• Primary Hypercholesterolaemia
• Mixed Hyperlipidaemia

Interventions

Type	Name	Description
DRUG	niacin (+) laropiprant	Duration of Treatment - 24 weeks
DRUG	ER-niacin	Duration of Treatment - 24 weeks

Timeline

• Start date: 2005-12-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2005-12-23
• Last updated: 2015-07-27